Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591.

Telix Pharmaceuticals has announced positive early-stage results from its global phase 3 trial of TLX591, an experimental treatment for advanced prostate cancer. The initial phase of the trial, ...

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...

Telix Pharmaceuticals reports positive Phase 3 safety results for its investigational prostate cancer therapy, TLX591-Tx. The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results ...

In a medical achievement that highlights how technology is reshaping modern healthcare, a surgeon in London has successfully carried out a complex cancer operation on a patient located roughly 1,500 ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...